4.2 Article

Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment

期刊

BIOMED RESEARCH INTERNATIONAL
卷 2021, 期 -, 页码 -

出版社

HINDAWI LTD
DOI: 10.1155/2021/8852699

关键词

-

资金

  1. National Key R&D Program of China [MOST-2017YFC0908300]
  2. Technological Special Project of Liaoning Province of China [2019020176-JH1/103]
  3. Natural Science Foundation of Liaoning Province of China [2019-MS-390]
  4. China Postdoctoral Science Foundation [2018M641746]
  5. Natural Science Foundation Medical and Health Joint Fund Project of Liaoning Province [20180530006]

向作者/读者索取更多资源

For patients with LARC who have received neoadjuvant treatment and surgery, adjuvant chemotherapy improves overall survival and disease-free survival compared to observation. However, adding oxaliplatin to fluorouracil-based adjuvant chemotherapy does not provide additional survival benefits.
Background. Neoadjuvant (chemo) radiotherapy is used as a standard treatment for locally advanced rectal cancer (LARC), but there is no general consensus on either the efficacy of postoperative adjuvant chemotherapy in patients with LARC after neoadjuvant treatment and surgery, or whether the addition of oxaliplatin to adjuvant chemotherapy provides survival benefits. Methods. We performed a meta-analysis of data from the PubMed and Embase databases. We included patients with LARC who received neoadjuvant (chemo) radiotherapy and curative surgery. Overall survival (OS), disease-free survival (DFS), toxicity, and compliance were analyzed in the oxaliplatin/fluorouracil- (OX/FU-) based group compared with the FU-based group, and in the chemotherapy group compared with the observation group. Results. Twenty studies were included in the analysis. Our results indicated that adjuvant chemotherapy prolonged OS (hazard ratio HR=0.78, 95%CI=0.67-0.91) in patients with LARC treated with neoadjuvant (chemo) radiotherapy and surgery compared with those in the observation group. Subgroup analysis showed the same results in both the ypStage II and ypStage III groups. Compared with those in the observation group, patients in the chemotherapy group also showed an increase in DFS (HR=0.75, 95%CI=0.60-0.93). No significant increase was observed in OS (HR=1.04, 95%CI=0.87-1.24) or DFS (HR=0.98, 95%CI=0.76-1.27) when oxaliplatin was added to FU-based adjuvant chemotherapy, as compared with the FU-based treatment, and subgroup analysis also indicated no survival benefits in the clinical stage II, clinical stage III, ypStage II, and ypStage III groups. Conclusions. For patients with LARC who have already received neoadjuvant (chemo) radiotherapy and curative surgery, adjuvant chemotherapy improves OS over that in the observation group. Adding oxaliplatin to FU-based adjuvant chemotherapy does not confer survival benefits beyond those from FU-based adjuvant chemotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据